Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16169
Title: Mutations of the sonic hedgehog pathway underlie hypothalamic hamartoma with gelastic epilepsy
Authors: Hildebrand, Michael S;Griffin, Nicole G;Damiano, John A;Cops, Elisa J;Burgess, Rosemary;Ozturk, Ezgi;Jones, Nigel C;Leventer, Richard J;Freeman, Jeremy L;Harvey, A Simon;Sadleir, Lynette G;Scheffer, Ingrid E;Major, Heather;Darbro, Benjamin W;Allen, Andrew S;Goldstein, David B;Kerrigan, John F;Berkovic, Samuel F;Heinzen, Erin L
Issue Date: 4-Aug-2016
EDate: 2016-07-21
Citation: American Journal of Human Genetics 2016; 99(2): 423-429
Abstract: Hypothalamic hamartoma (HH) with gelastic epilepsy is a well-recognized drug-resistant epilepsy syndrome of early life.(1) Surgical resection allows limited access to the small deep-seated lesions that cause the disease. Here, we report the results of a search for somatic mutations in paired hamartoma- and leukocyte-derived DNA samples from 38 individuals which we conducted by using whole-exome sequencing (WES), chromosomal microarray (CMA), and targeted resequencing (TRS) of candidate genes. Somatic mutations were identified in genes involving regulation of the sonic hedgehog (Shh) pathway in 14/38 individuals (37%). Three individuals had somatic mutations in PRKACA, which encodes a cAMP-dependent protein kinase that acts as a repressor protein in the Shh pathway, and four subjects had somatic mutations in GLI3, an Shh pathway gene associated with HH. In seven other individuals, we identified two recurrent and three single brain-tissue-specific, large copy-number or loss-of-heterozygosity (LOH) variants involving multiple Shh genes, as well as other genes without an obvious biological link to the Shh pathway. The Shh pathway genes in these large somatic lesions include the ligand itself (SHH and IHH), the receptor SMO, and several other Shh downstream pathway members, including CREBBP and GLI2. Taken together, our data implicate perturbation of the Shh pathway in at least 37% of individuals with the HH epilepsy syndrome, consistent with the concept of a developmental pathway brain disease.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16169
DOI: 10.1016/j.ajhg.2016.05.031
ORCID: 0000-0002-2311-2174
0000-0003-4580-841X
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/27453577
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.